Connect Biopharma Statistics
Share Statistics
Connect Biopharma has 55.35M
shares outstanding. The number of shares has increased by 0.27%
in one year.
| Shares Outstanding | 55.35M |
| Shares Change (YoY) | 0.27% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 5.77% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 10,246 |
| FTD / Avg. Volume | 9.36% |
Short Selling Information
The latest short interest is 48.52K, so 0.09% of the outstanding
shares have been sold short.
| Short Interest | 48.52K |
| Short % of Shares Out | 0.09% |
| Short % of Float | 0.16% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -4.88 and the forward
PE ratio is -0.31.
Connect Biopharma's PEG ratio is
0.07.
| PE Ratio | -4.88 |
| Forward PE | -0.31 |
| PS Ratio | 2.93 |
| Forward PS | 0.8 |
| PB Ratio | 0.83 |
| P/FCF Ratio | -3.13 |
| PEG Ratio | 0.07 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Connect Biopharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.46,
with a Debt / Equity ratio of 0.
| Current Ratio | 11.46 |
| Quick Ratio | 11.46 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $419,887.1 |
| Profits Per Employee | $-252,064.52 |
| Employee Count | 62 |
| Asset Turnover | 0.26 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 223K |
| Effective Tax Rate | -1.45% |
Stock Price Statistics
The stock price has increased by -61.03% in the
last 52 weeks. The beta is -0.29, so Connect Biopharma's
price volatility has been lower than the market average.
| Beta | -0.29 |
| 52-Week Price Change | -61.03% |
| 50-Day Moving Average | 0.76 |
| 200-Day Moving Average | 1.03 |
| Relative Strength Index (RSI) | 48.35 |
| Average Volume (20 Days) | 109,487 |
Income Statement
In the last 12 months, Connect Biopharma had revenue of 26.03M
and earned -15.63M
in profits. Earnings per share was -0.28.
| Revenue | 26.03M |
| Gross Profit | 25.37M |
| Operating Income | -22.45M |
| Net Income | -15.63M |
| EBITDA | -22.45M |
| EBIT | -22.45M |
| Earnings Per Share (EPS) | -0.28 |
Full Income StatementBalance Sheet
The company has 78.23M in cash and 178K in
debt, giving a net cash position of 78.05M.
| Cash & Cash Equivalents | 78.23M |
| Total Debt | 178K |
| Net Cash | 78.05M |
| Retained Earnings | -345.36M |
| Total Assets | 101.28M |
| Working Capital | 88.5M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -23.61M
and capital expenditures -750K, giving a free cash flow of -24.36M.
| Operating Cash Flow | -23.61M |
| Capital Expenditures | -750K |
| Free Cash Flow | -24.36M |
| FCF Per Share | -0.44 |
Full Cash Flow StatementMargins
Gross margin is 97.46%, with operating and profit margins of -86.24% and -60.03%.
| Gross Margin | 97.46% |
| Operating Margin | -86.24% |
| Pretax Margin | -59.17% |
| Profit Margin | -60.03% |
| EBITDA Margin | -86.24% |
| EBIT Margin | -86.24% |
| FCF Margin | -93.58% |
